• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Diphenylethers

Recent Advances in the Study of Hydrazine,[(4-phenoxyphenyl)methyl]- (CAS: 887594-18-5) in Chemical Biology and Pharmaceutical Research

The compound Hydrazine,[(4-phenoxyphenyl)methyl]-, identified by the CAS number 887594-18-5, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This hydrazine derivative has shown promising potential in various therapeutic applications, particularly in the development of novel enzyme inhibitors and targeted drug delivery systems. Recent studies have focused on elucidating its molecular mechanisms, pharmacokinetic properties, and therapeutic efficacy, making it a compound of high interest for researchers in the field.

One of the key areas of investigation has been the role of Hydrazine,[(4-phenoxyphenyl)methyl]- in enzyme inhibition. Preliminary studies suggest that this compound exhibits strong inhibitory effects on specific enzymes involved in inflammatory pathways, such as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX). These findings are particularly relevant for the development of new anti-inflammatory drugs, as the compound's unique structure allows for selective targeting of these enzymes, potentially reducing side effects associated with non-selective inhibitors.

In addition to its enzyme inhibitory properties, recent research has explored the potential of Hydrazine,[(4-phenoxyphenyl)methyl]- as a building block for the synthesis of more complex pharmaceutical agents. Its reactive hydrazine group makes it a versatile intermediate in the preparation of hydrazone-based prodrugs, which can be designed for targeted release in specific physiological environments. This approach has been particularly promising in the context of cancer therapy, where controlled drug release can enhance efficacy while minimizing systemic toxicity.

Another significant development has been the investigation of the compound's pharmacokinetic profile. Recent in vivo studies have demonstrated favorable absorption and distribution characteristics, with good bioavailability following oral administration. Moreover, metabolic stability studies have shown that Hydrazine,[(4-phenoxyphenyl)methyl]- undergoes predictable biotransformation pathways, which is crucial for its potential clinical application. These findings have paved the way for further optimization of the compound's structure to improve its drug-like properties.

Despite these promising results, challenges remain in the development of Hydrazine,[(4-phenoxyphenyl)methyl]- as a therapeutic agent. Current research is addressing issues related to its potential toxicity at higher doses and the need for improved selectivity. Advanced computational modeling and structure-activity relationship (SAR) studies are being employed to design derivatives with enhanced safety profiles while maintaining therapeutic efficacy. These efforts are expected to yield more optimized candidates for preclinical evaluation in the near future.

In conclusion, Hydrazine,[(4-phenoxyphenyl)methyl]- (CAS: 887594-18-5) represents a promising scaffold in medicinal chemistry with multiple potential applications. The recent advancements in understanding its biological activities and pharmacokinetic properties have positioned it as a valuable candidate for further drug development. Continued research in this area is likely to uncover additional therapeutic opportunities and contribute to the development of novel treatments for various diseases.

• 140-69-2([(4-methoxyphenyl)methyl]hydrazine)
• 85293-12-5((3-methoxyphenyl)methylhydrazine)
• 887596-61-4(3,5-Dimethoxy-benzyl-hydrazine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)